Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin.

Trial Profile

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2014

At a glance

  • Drugs Aprepitant; Dexamethasone; Ramosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 May 2010 Planned initiation date changed from 1 Jan 2010 to 1 May 2010 and trial phase changed from III to II as reported by ClinicalTrials.gov.
    • 17 May 2010 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 18 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top